No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Court Temporarily Restrains US Launch of Mylan’s/Biocon’s Eylea® (Aflibercept) Biosimilar
As previously reported, on 27 December 2023, and in a judgment published on 31 January 2024, the US District Court for the Northern District of West Virginia held that eight claims of Regeneron’s US patent 11,084,865, in respect of formulations of aflibercept such as...